KAP vs Psilocybin-Assisted Therapy
A side-by-side comparison of recorded mechanisms, evidence review status, related condition topics, and philosophical roots.
At a glance
Source checks, condition-specific assessments and expert review are separate steps. Each assessment applies only to its stated population and use. Topic links do not establish comparative effectiveness.
KAP
- Tradition
- Psychedelic
- Founder
- Various (Wolfson, Bennett) (2010)
- Review status
- 7 source checks available
- Official sources
Guidelines and official sources (7)
6 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- SPRAVATO (esketamine) original prescribing information
Not a treatment recommendation
The historical drug indication is verified. It does not establish approval or guideline endorsement of KAP. This original label is not current prescribing information.
Scope: Esketamine nasal spray plus an oral antidepressant for adult TRD in 2019
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD weakly suggests ketamine or esketamine augmentation. The recommendation concerns medication, not a named KAP psychotherapy protocol.
Scope: MDD after several adequate pharmacological trials have failed
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD weakly recommends against ketamine for PTSD. The statement concerns medication and does not separately evaluate KAP.
Scope: Ketamine pharmacotherapy for adult PTSD; not a separate KAP psychotherapy assessment.
- Assessment and Management of Patients at Risk for Suicide
Discussed in the source
VA/DoD weakly supports ketamine infusion for short-term ideation reduction; evidence for preventing attempts or suicide is insufficient. KAP is not separately recommended.
Scope: Adjunctive ketamine infusion in adults aged 18 and over with major depression and suicidal ideation; medication rather than KAP psychotherapy.
- Management of Major Depressive Disorder
Discussed in the source
VA/DoD suggests against ketamine/esketamine as initial pharmacotherapy (weak against). Its separate augmentation recommendation concerns prior treatment failure; neither recommendation endorses a named KAP psychotherapy protocol.
Scope: Adults choosing initial medication treatment for MDD.
- Management of Bipolar Disorder
Discussed in the source
VA/DoD finds insufficient evidence for ketamine/esketamine alone or as adjuncts. The recommendation concerns medication and does not endorse KAP psychotherapy.
Scope: Adults with acute bipolar depression.
- Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults
Discussed in the source
APA reports insufficient evidence for ketamine in these comparisons. This is a drug-level finding, not a separate evaluation of the KAP psychotherapy protocol.
Scope: Adults with PTSD; ketamine compared with an active or inactive intervention.
- SPRAVATO (esketamine) original prescribing information
- Focus
- Experiential + Processing
- Format
- Individual
- Duration
- Short-medium
Psilocybin-Assisted Therapy
- Tradition
- Psychedelic
- Founder
- Griffiths / Carhart-Harris (2016)
- Review status
- 1 condition assessment available
- Official sources
Guidelines and official sources (3)
2 clinical guideline checks · 1 regulatory source check
Read the recommendation and its scope. A source may discuss an approach without recommending it.
- FDA accelerates action on treatments for serious mental illness following Executive Order
Not a treatment recommendation
FDA announced priority vouchers for psilocybin studies in April 2026. This establishes development activity, not approval or psychotherapy endorsement.
Scope: Companies studying psilocybin for TRD and MDD
- Management of Major Depressive Disorder
Recommendation against the stated use
VA/DoD strongly recommends against psilocybin for MDD outside research. This 2022 guideline used evidence through January 2021 and does not review subsequent trials.
Scope: Psilocybin for MDD outside research settings
- Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder
Discussed in the source
VA/DoD finds insufficient evidence for or against psilocybin for PTSD. The statement does not separately establish a psychotherapy-protocol recommendation.
Scope: Psilocybin pharmacotherapy for adult PTSD; evidence reviewed through May 2022.
- FDA accelerates action on treatments for serious mental illness following Executive Order
- Focus
- Experiential + Processing
- Format
- Individual
- Duration
- Short (1-3 doses)
Condition-specific assessments
Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.
Existential & Meaning-Making Concerns
Population and scope: Carefully selected adults with a potentially life-threatening cancer diagnosis and anxiety/mood symptoms, receiving psilocybin with substantial preparation, monitored sessions and follow-up support.
Randomized studies
Griffiths et al. (2016) randomized dose order in a crossover study: 56 people were assigned and 51 completed at least one session. Higher-dose treatment favored several mood and existential outcomes compared with the very-low-dose condition, including life meaning and death acceptance. After crossover at five weeks, the six-month observations lacked an unexposed comparison. The small, predominantly White, highly educated sample, expectancy and masking limits, and intensive support restrict generalization. Transient anxiety, psychological distress and blood-pressure increases occurred. This is a trial-design assessment for that supervised research context, not a guideline endorsement or evidence for all meaning-making concerns or unsupervised use.
Source assessment dated
How they work
KAP
Core mechanism: Ketamine's dissociative state, and the plasticity that follows it, are treated as a window for psychotherapeutic processing and new learning; the window is proposed rather than demonstrated
Ontology: Treatment-resistant conditions involve rigid neural patterns; ketamine disrupts rigidity and opens plasticity window
Psilocybin-Assisted Therapy
Core mechanism: Psilocybin disrupts default mode network activity; on the standard account the mystical-type experience this can occasion is what produces lasting shifts in perspective and meaning, though whether that experience is necessary to the effect is actively disputed
Ontology: Rigid self-referential processing (depression) or compulsive patterns maintained by entrenched neural networks
Related condition topics
These editorial cross-references organize reading. A shared link does not mean both approaches are effective, recommended, or interchangeable for that condition.
2 shared · 2 KAP-only · 1 Psilocybin-Assisted Therapy-only
Linked to both entries
Linked only in the KAP entry
Linked only in the Psilocybin-Assisted Therapy entry
What each assumes — and misses
KAP
Philosophical roots: James (varieties of religious experience: altered states as data); Grof (non-ordinary states); Wolfson (ketamine as psychedelic medicine rather than anesthetic adjunct); neuroplasticity research
Blind spots: Regulatory fragmentation; limited standardization of psychotherapy component; risk of ketamine becoming the treatment rather than catalyst
Therapeutic voice: Last week you kept coming back to 'none of it is solid.' Let's stay there. What have you been treating as solid?
Psilocybin-Assisted Therapy
Philosophical roots: James (mystical experience); Huxley (doors of perception, reducing valve theory); Watts (ego dissolution); Buddhist concepts (non-self, interconnection); Carhart-Harris (entropic brain hypothesis)
Blind spots: Not FDA approved; challenging experiences can be destabilizing; standardization of therapy component still developing
Therapeutic voice: Whatever comes, let it come. Whatever goes, let it go. Trust the process.
Choosing between them
KAP and Psilocybin-Assisted Therapy both sit within the Psychedelic tradition — they share a worldview about what suffering is and how change happens. Differences are more often about technique and emphasis than about underlying theory.
For deeper coverage: see the full KAP and Psilocybin-Assisted Therapy pages, or use the interactive comparison tool to add more modalities to this comparison.